CMB International Securities  Equity Research  Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Healthcare Sector
Jill WU CFA
Sam HU PhD
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
Source SZSE
Source Bloomberg
12-mth Price Performance
Source Bloomberg
Auditor BDO CHINA
Related reports
Strong momentum continued  30 Apr
Strengthening global presence  1
Better business recovery outlook in
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP
RMB19304)
UpDownside
 1H21 earnings beat Tigermed reported 1H21 revenue attributable net profit
of RMB2056mn RMB1255mn increased by 42% 26% YoY accounting for
48% 88% of our full-year estimate Attributable recurring net profit grew 79%
YoY to RMB543mn in 1H21 which accounted for 58% of our full-year estimate
Tigermed booked RMB906mn fair value gains and RMB113mn investment
gains in 1H21 totaling 64% of its total net profit Despite negative impact from
RMB appreciation Tigermeds overseas revenue still registered a remarkable
55% YoY growth in 1H21 contributing 54% of the Companys total revenue
 Expect the recovery trend to continue in 2021 During 1H21 Tigermeds
new bookings reached RMB50748mn representing a 1508% YoY growth
Such a strong growth was driven by 1) increasing RD spending in innovation
therapies and medical devices 2) recovery of RD activities from the
pandemic and 3) the increased demand of clinical trials for COVID-19
vaccines and therapies Revenue from clinical trial solutions (CTS) reached
RMB1034mn in 1H21 up 45% YoY while the growth was primarily driven by
the increased revenue from clinical trial operation services As of 30 Jun 2021
Tigermed is conducting 491 ongoing drug clinical research projects up from
Tigermed In addition revenue generated from clinical-related laboratory
services (CRLS) increased 380% YoY to RMB10228mn mainly thanks to
the recovery of operation of US lab services and SMO services from the
 Accelerating global expansion driven by booming demand As Chinese
in global markets Tigermed benefits from increasing overseas clinical trial
demand from Chinese clients  Having been a pioneer in global expansion as
of 30 Jun 2021 Tigermed is conducting 111 single region clinical trials
overseas and 29 MRCTs During 1H21 Tigermed has acquired over
RMB800mn new MRCT bookings with bidding successful rate reaching over
30% Tigermed grew its number of overseas-based employee from 772 by
end-2020 to 854 by mid-2021 with strong presence across the Asia-Pacific
region North America Europe Latin America and Africa
 Maintain BUY We revised up our FY21E 22E 23E attributable net profit
forecasts by 48% 19% 18% to reflect the strong growth outlook We lifted our
new DCF-based TP to RMB19840 (WACC 984% Terminal growth 30%)
(YE 31 Dec)
Revenue (RMB mn)
Revenue YoY growth (%)
EPS YoY growth (%)
Net gearing (%)
Source Company data Bloomberg CMBIS estimates
Tigermed (300347 CH)
Strong backlog growth driven by solid demand
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 CMBIS Earnings revisions
1490 ppt
Source Company data CMBIS estimates
Figure 2 CMBIS estimates vs consensus
-1854 ppt
-1575 ppt
-1348 ppt
Source Company data Bloomberg CMBIS estimates
Figure 1 Risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
 of shares (mn)
DCF per share (in RMB)
Source CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY23E  YE 31 Dec (RMB mn)
FY19A FY20A FY21E FY22E FY23E
7669  Total net profit
Clinical field service
3815  Depreciation and
Clinical test technical
3834  Change in working capital
20  Investment loss (gain)
(4028)  Other operating activities
3642  Operating cash flow
(34)  Capex
(222)  Purchase of investment
(890)  Other investing activities
RD expenses
(307)  Investing cash flow
Net proceeds from shares
Finance costs net
193  Bank borrowing
0  Acquisition of non-controlling
1154  Dividends and interests paid
Pre-tax profit
3536  Other financing activities
(698)  FX changes
2621  Net change in cash
Cash at the beginning of the
YE 31 Dec (RMB mn)
FY19A  FY20A
FY21E  FY22E  FY23E  YE 31 Dec
FY19A FY20A FY21E FY22E FY23E
Non-current assets
11572  Sales mix (%)
629  Clinical trial technical services
62  Clinical trial consulting services
0  Other business
1445  Total
Other non-current
Profit  loss ratios (%)
15868  Gross margin
12960  EBITDA margin
6  Pre-tax margin
Trade and bills receivables
1891  Net margin
Prepayments deposits and
28  Effective tax rate
1478  Current ratio (x)
0  Trade receivables turnover
181  Trade payables turnover
Other current liabilities
1296  Net debt to equity ratio (%)
Net cash Net cash Net cash Net cash Net cash
Non-current liabilities
508  Returns (%)
Other non-current
25454  Per share
3551  EPS (RMB)
Shareholders equity
21902  DPS (RMB)
BVPS (RMB)
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in
the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or
its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
CMBIS is not a registered broker-dealer in the United States  As a result CMBIS is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or
qualified as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA
Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report
is intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing
to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as
defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced
by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers
Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined
in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the
extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report